
    
      Approximately 300 subjects, recruited from approximately 80 study centers in the United
      States (US), Canada, and Europe will be randomized to DAXI for injection high dose, DAXI for
      injection low dose, or placebo group, respectively. Subjects will be stratified by treatment
      center and history of prior treatment with botulinum neurotoxin (BoNT).
    
  